Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - June 2019

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Fluticasone/formoterol (Flutiform®) has been accepted for use in the regular treatment of asthma in children aged 5 to 12 years where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate:

  • for patients not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting β2 agonist
  • or for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist

This product has already been accepted for use in adults and adolescents aged 12 years and above on the same basis.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - June 2019' on Email Share 'SMC Update - June 2019' on Delicious Share 'SMC Update - June 2019' on Digg Share 'SMC Update - June 2019' on Facebook Share 'SMC Update - June 2019' on reddit Share 'SMC Update - June 2019' on Twitter

atomic-wealth

No Comments to “SMC Update - June 2019”

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer